Foresight Diagnostics

Join our webinar on November 20th at 1:00 pm ET (10:00 am PT) to explore the latest advancements in minimal residual disease (#MRD) detection and monitoring in early-stage #lungcancer and #breastcancer. Led by David Kurtz, Chief Medical Officer of Foresight Diagnostics, this session will feature data presentations from leading experts Luc Cabel from Memorial Sloan Kettering Cancer Center and Maximilian Diehn from Stanford Health. Registration and more information here -> https://t.ly/FGqzU

Our lab at Foresight Diagnostics was built to support MRD-driven clinical trials for our biopharma and academic research partners. In our new video, CEO Jake Chabon, COO Sandra Close, CMO David Kurtz, and CBO John Truesdell share their thoughts on the distinctive features of our lab capabilities, including: -> Delivering optimal turnaround times for clinical trial samples -> Maintaining rigorous and strict standards to quality management -> Providing high throughput capacity to enable support of global trials Watch video to learn more about our lab: https://lnkd.in/eV394W8r #MRD #ctdna #clinicaltrials #lymphoma

The core objective of #PrecisionMedicine is to deliver the right therapy to the right patient at the right time. While advancements in biomarker-based diagnostics and targeted therapies enhance our ability to identify "the right patient" and "the right drug," the question of timing remains crucial.     In his presentation at the Advancing Precision Medicine conference, Mark Roschewski highlighted how ultra-sensitive #ctDNA detection can help pinpoint the time point to explore alternative treatment strategies that, ultimately, may help improve cure rates in first-line settings in #lymphoma.     Strategies discussed include:     Risk-adapted approaches -> investigating whether pre-treatment ctDNA levels impact response to 1L therapy Response-adapted approaches -> adjusting strategies based on mid-treatment ctDNA levels  Early-salvage approaches -> continuing treatment for patients with persistent MRD after first-line therapy to prevent relapse.     By integrating precise, real-time tools like Foresight CLARITY at critical patient timepoints, we have the opportunity to rethink traditional treatment paradigms and enhance personalized clinical decision-making. 

#ForesightDx is looking forward to attending the Advancing Precision Medicine Conference in Philadelphia, PA, on November 1 and 2. Our research partner Dr. Mark Roschewski will discuss how advancements in ultra-sensitive #ctDNA technology may help evolve the precision medicine landscape in #lymphoma. Please join us for his presentation on November 1st at 4:45pm ET. Our Chief Business Officer John Truesdell and our Chief Operating and Compliance Officer Sandra Close will be attending. Interested in meeting? Schedule time to meet with our team here: Online: https://t.ly/FWBrA Email: BD@foresight-dx.com #PrecisionMedicine #AdvancingPrecisionMedicine #LiquidBiopsy #MRD #ForesightCLARITY #CancerResearch

#ForesightDx had an amazing time participating in The Susan G. Komen More Than Pink Walk this past weekend. Thank you to everyone who donated to our team. It was great to #connect to our #mission and see first hand the #impact our work could have on people affected by #cancer. See our most recent data in breast cancer here: https://t.ly/A2aQY #BreastCancerAwareness #MorethanPink #PinkWalk #PrecisionMedicine #LiquidBiopsy #MRD #ForesightCLARITY

Our partner Allogene Therapeutics will be speaking at the STAT Summit Conference on October 16th and 17th to discuss innovation in CAR T.     For more information and to register: https://t.ly/lKza2 #MRD #ctDNA #PrecisionMedicine #LiquidBiopsy #CancerResearch #ForesightDx #CART

#ForesightDx is proud to support organizations dedicated to improving the lives of cancer patients worldwide. In line with this mission, we invite you to help us raise money at our next volunteer event: The Susan G. Komen Foundation More than Pink Walk on Saturday October 12, 2024.    Please see our donation page here: https://t.ly/UezTP If you're able, we encourage you to donate to our team—every contribution makes a difference! #MorethanPink #BreastCancerAwareness #PinkWalk #MRD #CancerResearch #Fundraising

#ForesightDx proudly supports Breast Cancer Awareness Month, raising awareness and standing with those affected. Breast cancer mortality has decreased due to improved screening and treatment options. Nevertheless, 25-30% of patients develop disease #recurrence. Minimal residual disease (#MRD) detection has the opportunity to identify risk of #relapse sooner to improve our ability to #treat patients effectively. Let us continue to raise awareness on the importance of bringing #surveillance and early #detection technologies to clinicians and patients. Check out our recent poster showcasing new data on Foresight CLARITY™ ultra-sensitive MRD platform in early-stage breast cancer: https://t.ly/GIv9u #BreastCancerAwareness #BreastCancer #October #ThinkPink #ThinkBeforeYouPink #ForesightCLARITY #PrecisionMedicine #ctDNA

#ForesightDx had an amazing time participating in The Leukemia & Lymphoma Society's Light The Night walk in Denver, CO. A huge thank you to everyone who donated to support treatments for patients battling all forms of blood cancer. We look forward to joining this incredible cause again next year. #LightTheNight #LLS #ForesightCLARITY #BloodCancerAwarenessMonth #PrecisionMedicine #LiquidBiopsy

#ForesightDx proudly recognizes World Cancer Research Day, raising awareness of the vital role #cancer research plays in driving advancements in #prevention, #treatment, and #survival rates—helping to reduce the global cancer burden.  See our latest research in cancer relapse detection using our ultra-sensitive liquid biopsy platform, Foresight CLARITY ™: https://t.ly/V7Sid #WorldCancerResearchDay #CancerResearch #LiquidBiopsy #PrecisionMedicine #ForesightCLARITY #MRD #ctDNA